Clinical trial

AASUR in High Risk Prostate Cancer

NCT02772588

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2016-05-12

PhasePHASE2

Study timeline

Study start (actual)2016-05-12Date precision: day

Registry last updated2026-04-13

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Prostate Cancerunresolved

Interventions

AbirateroneDRUG · verified · RxNorm: abiraterone

LeuprolideDRUG · verified · RxNorm: leuprolide

stereotactic, ultra-fractionated radiotherapyRADIATION

Sponsors & collaborators

Memorial Sloan Kettering Cancer Centerlead sponsor

Janssen Pharmaceuticalscollaborator

Weill Medical College of Cornell Universitycollaborator

University of Michigancollaborator

Mapped research locations

New YorkNew York, United States2 PhiladelphiaPennsylvania, United States1 BaltimoreMaryland, United States1 Ann ArborMichigan, United States1 CommackNew York, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02772588 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.